Matteis covers the Healthcare sector, focusing on stocks such as Definium Therapeutics, ACADIA Pharmaceuticals, and Alkermes. According to TipRanks, Matteis has an average return of 17.8% and a 53.75% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $32.43 average price target.
Based on ACADIA Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $268.06 million and a net profit of $3.64 million. In comparison, last year the company earned a revenue of $244.32 million and had a net profit of $18.99 million
